Emergent BioSolutions (EBS) Non-Current Assets (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Non-Current Assets of $682.8 million for Q1 2026, down 5.07% year-over-year from $719.3 million in Q1 2025, and up 4.07% quarter-over-quarter from $656.1 million in Q4 2025.
Emergent BioSolutions (EBS) Non-Current Assets (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Non-Current Assets history runs 17 years deep, the most recent figure standing at $682.8 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 5.07% year-over-year to $682.8 million; the TTM figure through Mar 2026 stood at $2.7 billion (down 14.91% YoY), while the FY2025 annual figure was $656.1 million, down 17.05% from the prior year.
- Non-Current Assets for Q1 2026 stood at $682.8 million, up from $656.1 million in the prior quarter.
- The five-year high for Non-Current Assets was $2.0 billion in Q4 2022, with the low at $656.1 million in Q4 2025.
- The 5-year median for Non-Current Assets is $1.1 billion (2024), against an average of $1.1 billion.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets advanced 15.88% in 2022, then slumped 41.53% in 2023.
- Emergent BioSolutions' Non-Current Assets stood at $2.0 billion in 2022, then plunged by 41.53% to $1.1 billion in 2023, then plunged by 30.84% to $791.0 million in 2024, then dropped by 17.05% to $656.1 million in 2025, then climbed by 4.07% to $682.8 million in 2026.
- Business Quant data shows EBS's Non-Current Assets at $682.8 million in Q1 2026, $656.1 million in Q4 2025, and $674.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 450.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 450.80 Mn |
| Mar 31, 2026 | 682.80 Mn |
| Dec 31, 2025 | 656.10 Mn |
| Sep 30, 2025 | 674.10 Mn |
| Jun 30, 2025 | 697.60 Mn |
| Mar 31, 2025 | 719.30 Mn |
| Dec 31, 2024 | 791.00 Mn |
| Sep 30, 2024 | 816.40 Mn |
| Jun 30, 2024 | 859.00 Mn |
| Mar 31, 2024 | 1.12 Bn |
| Dec 31, 2023 | 1.14 Bn |
| Sep 30, 2023 | 1.17 Bn |
| Jun 30, 2023 | 1.40 Bn |
| Mar 31, 2023 | 1.73 Bn |
| Dec 31, 2022 | 1.96 Bn |
| Sep 30, 2022 | 1.80 Bn |
| Jun 30, 2022 | 1.65 Bn |
| Mar 31, 2022 | 1.68 Bn |
| Dec 31, 2021 | 1.69 Bn |
| Sep 30, 2021 | 1.76 Bn |